These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31768400)

  • 1. Fragment screening for a protein-protein interaction inhibitor to WDR5.
    Dennis ML; Morrow BJ; Dolezal O; Cuzzupe AN; Stupple AE; Newman J; Bentley J; Hattarki M; Nuttall SD; Foitzik RC; Street IP; Stupple PA; Monahan BJ; Peat TS
    Struct Dyn; 2019 Nov; 6(6):064701. PubMed ID: 31768400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.
    Ye X; Zhang R; Lian F; Zhang W; Lu W; Han J; Zhang N; Jin J; Luo C; Chen K; Ye F; Ding H
    Bioorg Med Chem Lett; 2019 Feb; 29(4):638-645. PubMed ID: 30626558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting WDR5: A WINning Anti-Cancer Strategy?
    Aho ER; Weissmiller AM; Fesik SW; Tansey WP
    Epigenet Insights; 2019; 12():2516865719865282. PubMed ID: 31360909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
    Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK
    Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction.
    Bolshan Y; Getlik M; Kuznetsova E; Wasney GA; Hajian T; Poda G; Nguyen KT; Wu H; Dombrovski L; Dong A; Senisterra G; Schapira M; Arrowsmith CH; Brown PJ; Al-Awar R; Vedadi M; Smil D
    ACS Med Chem Lett; 2013 Mar; 4(3):353-7. PubMed ID: 24900672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of
    Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
    J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
    Getlik M; Smil D; Zepeda-Velázquez C; Bolshan Y; Poda G; Wu H; Dong A; Kuznetsova E; Marcellus R; Senisterra G; Dombrovski L; Hajian T; Kiyota T; Schapira M; Arrowsmith CH; Brown PJ; Vedadi M; Al-Awar R
    J Med Chem; 2016 Mar; 59(6):2478-96. PubMed ID: 26958703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide.
    Patel A; Dharmarajan V; Cosgrove MS
    J Biol Chem; 2008 Nov; 283(47):32158-61. PubMed ID: 18829459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.
    Li DD; Chen WL; Xu XL; Jiang F; Wang L; Xie YY; Zhang XJ; Guo XK; You QD; Sun HP
    Eur J Med Chem; 2016 Aug; 118():1-8. PubMed ID: 27116709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.
    Karatas H; Li Y; Liu L; Ji J; Lee S; Chen Y; Yang J; Huang L; Bernard D; Xu J; Townsend EC; Cao F; Ran X; Li X; Wen B; Sun D; Stuckey JA; Lei M; Dou Y; Wang S
    J Med Chem; 2017 Jun; 60(12):4818-4839. PubMed ID: 28603984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.
    Teuscher KB; Chowdhury S; Meyers KM; Tian J; Sai J; Van Meveren M; South TM; Sensintaffar JL; Rietz TA; Goswami S; Wang J; Grieb BC; Lorey SL; Howard GC; Liu Q; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211297120. PubMed ID: 36574664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
    Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
    Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.
    Tian J; Teuscher KB; Aho ER; Alvarado JR; Mills JJ; Meyers KM; Gogliotti RD; Han C; Macdonald JD; Sai J; Shaw JG; Sensintaffar JL; Zhao B; Rietz TA; Thomas LR; Payne WG; Moore WJ; Stott GM; Kondo J; Inoue M; Coffey RJ; Tansey WP; Stauffer SR; Lee T; Fesik SW
    J Med Chem; 2020 Jan; 63(2):656-675. PubMed ID: 31858797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design.
    Wang F; Jeon KO; Salovich JM; Macdonald JD; Alvarado J; Gogliotti RD; Phan J; Olejniczak ET; Sun Q; Wang S; Camper D; Yuh JP; Shaw JG; Sai J; Rossanese OW; Tansey WP; Stauffer SR; Fesik SW
    J Med Chem; 2018 Jul; 61(13):5623-5642. PubMed ID: 29889518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.
    Karatas H; Townsend EC; Bernard D; Dou Y; Wang S
    J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
    Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
    Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5.
    Senisterra G; Wu H; Allali-Hassani A; Wasney GA; Barsyte-Lovejoy D; Dombrovski L; Dong A; Nguyen KT; Smil D; Bolshan Y; Hajian T; He H; Seitova A; Chau I; Li F; Poda G; Couture JF; Brown PJ; Al-Awar R; Schapira M; Arrowsmith CH; Vedadi M
    Biochem J; 2013 Jan; 449(1):151-9. PubMed ID: 22989411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.
    Ding J; Liu L; Chiang YL; Zhao M; Liu H; Yang F; Shen L; Lin Y; Deng H; Gao J; Sage DR; West L; Llamas LA; Hao X; Kawatkar S; Li E; Jain RK; Tallarico JA; Canham SM; Wang H
    J Med Chem; 2023 Jun; 66(12):8310-8323. PubMed ID: 37307526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders.
    Gurung R; Om D; Pun R; Hyun S; Shin D
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity.
    Aho ER; Wang J; Gogliotti RD; Howard GC; Phan J; Acharya P; Macdonald JD; Cheng K; Lorey SL; Lu B; Wenzel S; Foshage AM; Alvarado J; Wang F; Shaw JG; Zhao B; Weissmiller AM; Thomas LR; Vakoc CR; Hall MD; Hiebert SW; Liu Q; Stauffer SR; Fesik SW; Tansey WP
    Cell Rep; 2019 Mar; 26(11):2916-2928.e13. PubMed ID: 30865883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.